Sign in to view content

Canadian Treat-and-Extend Trial With Ranibizumab in nAMD Patients: CANTREAT 36-Month Extension Results

Peter J. Kertes, MD, FRCS(C)

Video
Published 2020

Related

Imaging Signatures and Cytokine Expression in Diabetic Macular Edema From the IMAGINE Study: Biomarker Exploration for Precision Medicine
Sruthi Arepalli, MD
On Demand Cases, Courses, and Papers
2020
Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab: From PRN Refills in Phase 2 Ladder to Fixed 24-Week Refills In Phase 3 Archway
Dilsher S. Dhoot, MD
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more